Epizyme (NASDAQ:EPZM) CEO Robert J. Gould sold 30,000 shares of the company’s stock on the open market in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $31.53, for a total transaction of $945,900.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Epizyme (NASDAQ:EPZM) traded down 1.61% on Monday, hitting $33.6895. The stock had a trading volume of 71,172 shares. Epizyme has a one year low of $18.10 and a one year high of $45.72. The stock has a 50-day moving average of $26.0 and a 200-day moving average of $26.53. The company’s market cap is $1.108 billion.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.47) by $0.25. Analysts expect that Epizyme will post $-1.78 EPS for the current fiscal year.
Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.